Website
N/ATelephone
61.3.9824.5254
Address
Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053
Description
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.07 - 0.2
Trade Value (12mth)
AU$9,624.00
1 week
0%
1 month
-6.58%
YTD
-31.66%
1 year
-34.63%
All time high
0.451941
EPS 3 yr Growth
N/A
EBITDA Margin
%
Operating Cashflow
-$23m
Free Cash Flow Return
-43.20%
ROIC
-64.50%
Interest Coverage
-429.70
Quick Ratio
1.20
Shares on Issue (Fully Dilluted)
359m
HALO Sector
Healthcare
Next Company Report Date
26-Sep-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Entitlement Offer to raise approximately $10 million
×
Entitlement Offer to raise approximately $10 million |
31 October 23 |
Investor Presentation - Entitlement Offer
×
Investor Presentation - Entitlement Offer |
31 October 23 |
Proposed issue of securities - RAD
×
Proposed issue of securities - RAD |
31 October 23 |
Investor webinar
×
Investor webinar |
31 October 23 |
Proposed issue of securities - RAD
×
Proposed issue of securities - RAD |
31 October 23 |
Entitlement Offer cleansing notice under section 708AA
×
Entitlement Offer cleansing notice under section 708AA |
31 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Change of Director's Interest Notice - RC
×
Change of Director's Interest Notice - RC |
31 October 22 |
Change of Director's Interest Notice - PH
×
Change of Director's Interest Notice - PH |
31 October 22 |
Change in substantial holding - PH
×
Change in substantial holding - PH |
31 March 22 |
Change of Director's Interest Notice - HL
×
Change of Director's Interest Notice - HL |
31 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 August 23 |
Appendix 4E and FY23 Financial Report
×
Appendix 4E and FY23 Financial Report |
31 August 22 |
Appendix 4E and Preliminary Final Report
×
Appendix 4E and Preliminary Final Report |
30 September 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 22 |
Corporate Governance Statement
×
Corporate Governance Statement |
30 September 22 |
Appendix 4G
×
Appendix 4G |
30 September 22 |
ESG Report
×
ESG Report |
30 September 22 |
Corporate Governance Statement
×
Corporate Governance Statement |
30 May 22 |
Notification regarding unquoted securities - RAD
×
Notification regarding unquoted securities - RAD |
30 June 23 |
Notification regarding unquoted securities - RAD
×
Notification regarding unquoted securities - RAD |
30 June 23 |
Notification of cessation of securities - RAD
×
Notification of cessation of securities - RAD |
30 December 22 |
aVb6 Integrin (RAD301) IND approval for Phase 1 trial
×
aVb6 Integrin (RAD301) IND approval for Phase 1 trial |
29 November 22 |
Change of Director's Interest Notice - PH
×
Change of Director's Interest Notice - PH |
29 November 22 |
Change of Director's Interest Notice - RC
×
Change of Director's Interest Notice - RC |
29 November 21 |
Investor Presentation
×
Investor Presentation |
29 May 23 |
FDA Pre-IND meeting supports an IND application for RAD 101
×
FDA Pre-IND meeting supports an IND application for RAD 101 |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.